About
Berry Oncology, founded in 2017 as a member company of Berry Genomics, focuses on genomic testing of cancers. Driven by the mission of "Diagnose all cancers early, treat all patients precisely", we have established for cancer patients and high-risk population a complete system of genomic testing products and services, including cancer genetic susceptibility analysis, early screening, as well as as companion diagnostics, response monitoring and prognosis prediction of both targeted and immune therapies. For cancer early detection, we have launched a series of clinical research projects for early screening and early diagnosis, covering liver cancer, lung cancer, gynecologic cancer, and etc. Berry Oncology has three centers (manufacture, supercomputing, R&D) located in Fuzhou and Beijing. We serve and cooperate with more than 600 Class 3A tertiary hospitals across the country, and have provided valuable genomic testing services for hundreds of thousands of patients.
View original content to download multimedia:https://www.prnewswire.com/news-releases/berry-oncology-completes-series-b1-funding-attracting-most-venture-capital-to-date-in-early-cancer-screening-sector-301349029.html
Beijing